Merck & Co Inc. (NYSE:MRK) on Monday said its investigational therapy tulisokibart achieved the primary endpoint in a Phase 3 study in moderately to severely active ulcerative colitis (UC), marking what the company described as the first positive Phase 3 induction results for an anti-TL1A biologic.
Positive Data For Tulisokibart In Ulcerative Colitis
The company announced that the Phase 3 ATLAS-UC induction-only study, also known as Study 2, met its primary endpoint of clinical remission at week 12 based on the Modified Mayo Score. The trial also achieved key secondary endpoints.
Merck added that the safety profile observed in the study was consistent with previously reported Phase 2 findings, with no new safety concerns identified.
Read Next
